ClinicalTrials.gg
CompletedNCT01357603Updated Jan 25, 2013

Comparative Glucose Clamp Study of Wockhardt's Recombinant Insulin Analog Glargine(Glaritus) With Lantus in T1DM

A Phase 1 interventional study of Glargine in Type1 Diabetes, sponsored by Wockhardt. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2013-01-25.

Sponsored by Wockhardt · Phase 1, Interventional, and Health services research

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
111
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1 — none open to participants now, none under way, none of them phase 3. Insulin Glargine · Diabetes Mellitus, Type 1.

Enrollment
27th of 66
111 · median 73
Started
2011
with 7 others
Phase 1
14 of 66
none open now
Registered
29th of 66
by date

Among the 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1, this one is the 27th largest by enrollment, is one of 8 that started in 2011, is one of 14 in phase 1, and was the 29th registered.

Diabetes Mellitus, Type 1

3,757 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

None of the 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1 is open now. The open studies under Diabetes Mellitus, Type 1, anywhere →

About Insulin Glargine

Insulin Glargine: first FDA approval 2000 (LANTUS SOLOSTAR), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 416 Diabetes Mellitus, Type 1 studies recruiting now, 129 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1 as a file.
02

Study summary

The aim of this trial is to demonstrate bioequivalence of Glaritus® to Lantus® with regard to its total and to its maximum serum insulin concentrations.

Read the detailed description

The purpose of this study is to test for bioequivalence based on the pharmacokinetic parameter AUC INS-GLR 0-24h and on pharmacodynamic parameter AUC GIR 0-24h between the two long-acting insulin glargine formulations, Lantus® and Wockhardt's Glaritus® in subjects with type1 diabetes as well as assessing safety and local tolerability of the two insulin preparations.

03

Conditions studied

  • Type1 Diabetes
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects with type 1 diabetes ≥12 months.
  2. ≤9% by local laboratory analysis (one retest within a week is permitted with the result of the last test being conclusive).
  3. Age ≥18 and ≤60 years.
  4. Considered generally healthy upon completion of medical history, physical examination and biochemical investigations as judged by the Investigator.
  5. Signed and dated obtained before any trial-related activities. (Trial-related activities are any procedure that would not have been performed during normal management of the subject).

Exclusion criteria

Exclusion Criteria:

  1. Previous participation in this trial, or participation in other clinical trials within the last 30 days.
  2. Pregnant, breast-feeding or the intention of becoming pregnant or not using adequate measures (e.g. intrauterine device (IUD) that has been in place for at least 3 months, or sterilization, or the oral contraceptive pill, which should have been taken without difficulty for at least 3 months, an approved hormonal implant or double barrier method including male condoms used plus spermicide, diaphragm with spermicide plus male condom, cap with spermicide plus male condom).
  3. History of any illness that, in the opinion of the Investigator, might confound the results of the trial or pose risk in administering the trial drug to the subject. In particular, subjects with significant cardiovascular disease, anemia ( below the lower limit of normal) or hemoglobinopathy will not be allowed to enter the trial.
  4. Cardiac problems defined as decompensated heart failure ( (NYHA) class III and IV) at any time and/or angina pectoris within the last 12 months and/or acute myocardial infarction at any time.
  5. abnormal at screening, as judged by the Investigator.
  6. History of alcohol or drug abuse in the past five years.
  7. Any positive reaction of drug abuse.
  8. or C or positive.
  9. Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.
  10. History of multiple and/or severe allergies to drugs or foods or a history of severe anaphylactic reaction.
  11. Regular cigarette smoker, defined as smoking >1 pack/day and unable to refrain from smoking during the in house period.
  12. Known or suspected allergy to trial product or related products.
  13. Any disease or condition that, in the opinion of the Investigator, would represent an unacceptable risk for the subject's safety.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
111 participants (actual)

Study arms

  • Experimental
    Glaritus arm

    Insulin glargine (Glaritus: 100 U/ml), Penfill® cartridges 3.0ml

    Biological: Glargine

  • Active comparator
    Lantus arm

    Insulin glargine (Lantus: 100 U/ml), Penfill® cartridges 3.0ml

    Biological: Glargine

Interventions

06

What researchers measure

Primary outcomes

  1. Bioequivalence based on Pharmacokinetic parameter:AUC INS-GLR 0-24h.

    Time frame: over 24hrs post dose

  2. Bioequivalence based on Pharmacodynamic parameter: AUC GIR 0-24hrs

    Time frame: over 24hrs post dose

  3. Pharmacokinetic Parameters: Maximum concentration (Cmax)

    Time frame: over 24hrs post dose

Secondary outcomes

  1. Safety parameters

    Number of AE's, SAE's, Hypoglycemic events and local tolerability

    Time frame: till 24 hrs post-dose

  2. Pharmacodynamic parameters: Area under curve glucose infusion rate from 0-24hrs

    AUC GIR 0-12h,AUC GIR 12-24h,AUC GIR 0-24h

    Time frame: over 24hrs post dose

  3. Pharmacokinetic parameter: Area under curve from 0-24hrs

    AUC INS-GLR 0-12hrs, AUC INS-GLR 12-24hrs,AUC INS-GLR 0-24hrs

    Time frame: over 24hrs post dose

  4. Pharmacokinetic Parameters: tmax and t1/2

    Time frame: over 24hrs post dose

  5. Pharmacodynamic parameter: GIR max and tGIR max

    Time frame: over 24hrs post dose

07

Study locations

1 site
  • Profil Institute for clinical Research
    Chula Vista, California 91911, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2011, a primary completion of May 2012 and a completion of Aug 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2011
First posted
May 20, 2011
Start
Jun 2011
Primary completionActual
May 2012
CompletionActual
Aug 2012
Last update
Jan 25, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 25, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01357603
Lead sponsor
Wockhardt
Responsible party
Sponsor
First posted
May 20, 2011
Start date
Jun 2011
Primary completion
May 2012
Completion
Aug 2012
Last update
Jan 25, 2013

Study contacts

Dr. Elaine Watkins
principal investigator · Profil Institute of Clinical Research

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin Glargine

Start the discussion